PCM
APRE icon

Penserra Capital Management’s Aprea Therapeutics APRE Stock Holding History

Penserra Capital Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25
Closed -$2K – 1368
2021
Q3 		$2K Buy
25
+1
+4% +$91 ﹤0.01% 1434
2021
Q2 		$2K Hold
24
– – ﹤0.01% 1333
2021
Q1 		$2K Hold
24
– – ﹤0.01% 1101
2020
Q4 		$2K Buy
+24
New +$11.4K ﹤0.01% 993

Other funds holding APRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Penserra Capital Management's APRE Position: Q4 2021 in Review

Penserra Capital Management sold out of Aprea Therapeutics (APRE) in Q4 2021, closing a stake of 25 shares — an estimated $2K sold.

Penserra Capital Management first reported a position in APRE in Q4 2020 and held it in 4 quarters. The position peaked at $2K in Q3 2021. 41 funds tracked by Wall St. Rank hold APRE as of Q4 2021.

  • Penserra Capital Management reported no remaining Aprea Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 25 Aprea Therapeutics shares in Q4 2021, an estimated $2K.
  • Penserra Capital Management first reported a position in Aprea Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Aprea Therapeutics position peaked at $2K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.